These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 1319303

  • 21. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Kayser FH, Wüst J.
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):163-6. PubMed ID: 2060516
    [Abstract] [Full Text] [Related]

  • 22. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS, Jones RN, Erwin ME, Johnson DM, Briggs BM.
    Diagn Microbiol Infect Dis; 1991 Mar; 14(5):389-401. PubMed ID: 1665774
    [Abstract] [Full Text] [Related]

  • 23. Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing.
    Jones RN, Aldridge KE, Barry AL, Fuchs PC, Gerlach EH, Pfaller MA, Washington JA.
    Diagn Microbiol Infect Dis; 1988 Aug; 10(4):221-40. PubMed ID: 3072151
    [Abstract] [Full Text] [Related]

  • 24. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.
    Jones RN, Erwin ME, Gooding BB.
    J Clin Microbiol; 1992 Apr; 30(4):1022-3. PubMed ID: 1572959
    [Abstract] [Full Text] [Related]

  • 25. Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media.
    Jones RN, Barry AL, Thornsberry C.
    Diagn Microbiol Infect Dis; 1986 Apr; 4(4):345-9. PubMed ID: 3698547
    [Abstract] [Full Text] [Related]

  • 26. RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
    Fuchs PC, Jones RN, Barry AL, Ayers LW, Gavan TL, Gerlach EH, Thornsberry C.
    Diagn Microbiol Infect Dis; 1987 May; 7(1):29-35. PubMed ID: 3121241
    [Abstract] [Full Text] [Related]

  • 27. Proposed disk diffusion susceptibility criteria for ofloxacin.
    Fuchs PC, Barry AL, Jones RN, Thornsberry C.
    J Clin Microbiol; 1985 Aug; 22(2):310-1. PubMed ID: 3861612
    [Abstract] [Full Text] [Related]

  • 28. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
    Jones RN, Kugler KC, Erwin ME, Biedenbach DJ, Beach ML, Pfaller MA.
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):247-53. PubMed ID: 10212751
    [Abstract] [Full Text] [Related]

  • 29. Interpretive criteria for temocillin disk diffusion susceptibility testing.
    Fuchs PC, Barry AL, Thornsberry C, Jones RN.
    Eur J Clin Microbiol; 1985 Feb; 4(1):30-3. PubMed ID: 3872793
    [Abstract] [Full Text] [Related]

  • 30. In vitro study with ciprofloxacin: interpretive criteria of agar diffusion test according to standards of the NCCLS and DIN.
    Grimm H.
    Am J Med; 1987 Apr 27; 82(4A):376-80. PubMed ID: 3578326
    [Abstract] [Full Text] [Related]

  • 31. In vitro activity of CP-74,667. A new fluoroquinolone compared with other quinolones.
    Gu JW, Fang W, Chin NX, Neu HC.
    Diagn Microbiol Infect Dis; 1992 Apr 27; 15(7):613-20. PubMed ID: 1330421
    [Abstract] [Full Text] [Related]

  • 32. Selection of a fluoroquinolone-class disk for susceptibility tests.
    Barry AL, Fuchs PC.
    Am J Med; 1993 Mar 22; 94(3A):17S-22S. PubMed ID: 8383918
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-micrograms disks.
    Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1987 May 22; 7(1):77-82. PubMed ID: 3691036
    [Abstract] [Full Text] [Related]

  • 37. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG, Jones RN.
    J Antimicrob Chemother; 1995 Aug 22; 36(2):431-4. PubMed ID: 8522474
    [Abstract] [Full Text] [Related]

  • 38. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Chemotherapy; 1992 Aug 22; 38(2):99-106. PubMed ID: 1317282
    [Abstract] [Full Text] [Related]

  • 39. Disk diffusion susceptibility test interpretive criteria for GR69153, a new catechol-substituted cephalosporin.
    Jones RN, Erwin ME.
    J Clin Microbiol; 1991 Dec 22; 29(12):2890-2. PubMed ID: 1757568
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity of CP-74667 compared with four other fluoroquinolones.
    Jones RN, Erwin ME.
    Diagn Microbiol Infect Dis; 1992 Aug 22; 15(6):531-6. PubMed ID: 1330419
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.